Valeant Pharmaceutic
VRX
End-of-day quote Toronto Stock Exchange - 06/23
20.93CAD
+2.05%
Prev.20.5100
Open20.3200
High21.0000
Low19.7900
Volume2 404 246
Last news
Financials
Sales 2017 8 757 M
EBIT 2017 3 287 M
R. net 2017 -349 M
Debt 2017 25 910 M
Rend. 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 3,57x
EV / Sales 2018 3,36x
Capitalization 5 383 M
Company
Valeant Pharmaceuticals International, Inc. engages in the development, manufacture, and market of a broad range of pharmaceutical products in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics.It operates through the following segments: The Bausch +...
Sector :
Pharmaceuticals - NEC
Calendar : 2017-08-03 Earnings Release
Trading Rating :
Investor Rating :
Technical analysis trends
Short TermMid-TermLong Term
TrendBullishNeutralBearish
Resistance21,222,021,2
Spread/Res.-1,3%-5,0%-1,3%
Spread/Supp.17%83%83%
Support18,011,511,5